$AMBS The formation of Elto Pharma and MANF Therapeutics added to the already established wholly-owned subsidiary Cutanogen Corporation which is developing Engineered Skin Substitute (ESS) initially for the treatment of life-threatening pediatric severe burns.

https://financialstrend.com/two-themes-could-...46629.html